Why Stuart sees CAR Group accelerating
Why Stuart sees CAR Group accelerating
About this video
Key points:
Roberts views Carsales.com (ASX:CAR) as an AI-resilient, capital-light marketplace poised for a rebound
Ongoing heavy software and AI investment is seen as critical to Carsales’ global growth strategy
Neuren Pharmaceuticals (ASX:NEU) is regarded as a potential future ASX top 50 stock driven by its RET syndrome drug and pipeline
Stuart Roberts from Stocks Down Under sets out a bullish case for Carsales.com (ASX:CAR), arguing that established digital marketplaces with deep proprietary data are well placed against emerging artificial intelligence challengers. Roberts points to Carsales’ investment of around $120 million in software and AI tools, including a São Paulo-based team developing “genetic agents” that could handle virtual car inspections and price negotiations, as evidence of a proactive strategy to defend and grow its market position.
Roberts highlights Carsales’ half-year performance, noting revenue growth of about 8%, EBITDA above $300 million, and strong free cash flow after investment, which he says enables the group to stay on the offensive. He describes the business model as capital-light, supported by premium dealer listings and highly sticky subscriptions. Brands such as Trader Interactive in the US and platforms across South Korea, Brazil and Chile are viewed by Roberts as a scalable, global template.
Positioning Carsales as one of the “dogs of the ASX 200” set to rebound, Roberts frames the recent share price weakness as AI-driven fear rather than fundamentals. He contrasts Carsales’ ongoing software investment with Xero (ASX:XRO), which he claims is underinvesting in its platform. Roberts is also upbeat on Neuren Pharmaceuticals (ASX:NEU), citing European regulatory progress for its RET syndrome treatment and a fully owned pipeline that he contends could eventually propel Neuren into the ASX top 50.